Buy Libexin Muco syrup 20 mg/ml 125 ml
  • Buy Libexin Muco syrup 20 mg/ml 125 ml

Carbocysteine

A.Nattermann and Cie GmbH
1522 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$45.45
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Libexin Muko - mucolytic.

Pharmacodynamics

Carbocysteine, being a mucolytic, has an effect on the gel phase of the endobronchial secretion, breaking the disulfide bridges of glycoproteins and, thus, reducing the viscosity and increasing the elasticity of the secretion.

Carbocysteine ​​activates sialic transferase - the enzyme of the bronchial mucous membrane goblet cells, normalizes the quantitative ratio of acidic and neutral sialomucins, promotes the regeneration of the mucous membrane, normalizes its structure, activates the activity of the ciliary epithelium, restores the secretion of immunologically active IgA (specific protection), improves

Pharmacokinetics

Carbocysteine ​​is rapidly absorbed after ingestion, reaching Cmax in serum after 2 hours. Bioavailability is low (less than 10% of the dose taken) as a result of possible rapid passage through the liver. T1/2 - About 2 hours. It is excreted mainly by the kidneys along with metabolites.

Indications

Acute and chronic bronchopulmonary diseases, accompanied by the formation of viscous, difficult to separate sputum (tracheitis, bronchitis, tracheobronchitis, bronchial asthma, bronchiectasis) and mucus (inflammatory diseases of the middle ear, nose and sinuses - rhinitis, otitis media, sinusitis); preparing the patient for bronchoscopy or bronchography.

Composition

100 ml of syrup contains:

Active ingredient: carbocysteine2 g;

Excipients: sucrose - 70 g; methyl parahydroxybenzoate - 0.15 g; vanillin - 0.05 g; Ponso 4R crimson dye (cochineal red A - E124) - 0.005 g; raspberry flavoring - 1 ml; cherry flavoring - 0.5 ml; sodium hydroxide - q.s. to a pH of 6.1–6.3; purified water - up to 100 ml.

Carbocysteine is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Libexin Muco A.Nattermann and Cie GmbH Germany syrup
Bronchobos Bosnalek Bosnia and Herzegovina capsules
Bronchobos Bosnalek Bosnia and Herzegovina syrup
Fluifort Dompe Italy tea bags
Fluifort Dompe Italy syrup
Fluditec Innotech International France syrup

No customer reviews for the moment.

Write your review

Write your review

Carbocysteine

Dosage and Administration

For oral use

One measuring cup of syrup (15 ml) contains 750 mg of carbocysteine, 1 measuring spoon (5 ml) - 100 mg of carbocysteine.

For adults- one measuring cup (15 ml) 3 times a day, preferably separately from meals;children 2–5 years old - on 1 measured spoon 2 times a day (200 mg / days),older than 5 years- 1 scoop 3 times a day (300 mg / day).

The duration of treatment without consulting a doctor should not exceed 8 days.

Adverse reactions

On the part of the digestive tract: sometimes nausea, vomiting, diarrhea, epigastric pain, gastrointestinal bleeding.

On the part of the immune system: allergic skin rash and anaphylactic reactions, including urticaria, angioedema, exanthema, persistent erythema.

Skin and Subcutaneous Tissues: isolated cases of bullous dermatitis, including Stevens-Johnson syndrome and erythema multiforme (exudative).

Allergic reactions: itching, urticaria, rash, angioedema.

Other: dizziness, weakness, malaise.

Carefully: gastric ulcer and duodenal ulcer history, lactation.

Drug interactions

Karbotsistein increases the effectiveness of corticosteroids and antibacterial therapy of inflammatory diseases of the upper and lower respiratory tract, potentiates the bronchodilator effect of theophylline. The activity of carbocysteine ​​is weakened by antitussive and atropine-like agents.

Due to the alcohol content Libexin Muko® (for adults) is prescribed with caution with the following drugs: drugs that cause adverse reactions (fever, redness, vomiting, tachycardia) while being taken with alcoholic beverages - disulfiram, cefamandol, cefoperazone, latamoxfef (cephalosporin antibiotics), chloramphenicol (opfimol) (fylenomer) chlorpropamide, glibenclamide, glipizide, tolbutamide (sulfamide antidiabetic drugs), griseofulvin (antifungal drug), nitro-5-imidazoles (metronidazole, ornidazole, secnidazole, tinidazole), ketoconazole, pro carbazine (cytostatic); drugs that depress the central nervous system.

Special instructions

Alcohol content in Libexin Mucco® (for adults) is 1.64% by volume, i.e. 0.2 g of alcohol in a measuring cup. It can be dangerous for people with liver diseases, alcoholism, epilepsy, injuries or diseases of the brain, pregnant women.

When appointing Liebeksina Muko® patients with diabetes mellitus or patients on a low-carb diet should take into account the sucrose content - 6 g per measuring cup of syrup for adults or 3.5 g per measuring spoon of syrup for children.

When patients follow a salt-free or low-salt diet, the sodium content (97 mg) per measuring cup should be taken into account.

Influence on the ability to drive a car or perform work that requires increased speed of physical and mental reactions. Violation of the speed of psychomotor reactions associated with the presence of alcohol in the preparation may be dangerous when driving a car or working with mechanisms.

Overdosage

Symptoms: gastralgia, nausea, diarrhea.

Treatment: symptomatic.

  • Brand name: Libexin Muco
  • Active ingredient: Carbocysteine
  • Dosage form: Syrup for children
  • Manufacturer: A.Nattermann and Cie GmbH
  • Country of Origin: Germany

Studies and clinical trials of Carbocysteine (Click to expand)

  1. Relative bioavailability of carbocysteine from three dosage forms investigated in healthy volunteers
  2. Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients
  3. High-throughput determination of carbocysteine in human plasma by liquid chromatography/tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers
  4. Determination of carbocysteine in human plasma by liquid chromatography/tandem mass spectrometry employing precolumn derivatization
  5. Evaluation of proposed sulphoxidation pathways of carbocysteine in man by HPLC quantification
  6. The effect and mechanism of action of carbocysteine on airway bacterial load in rats chronically exposed to cigarette smoke
  7. Effects of combination therapy with montelukast and carbocysteine in allergen-induced airway hyperresponsiveness and airway inflammation
  8. CARBOCYSTEINE THERAPY IN OLDER PEOPLE WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  9. Kinetic determination of carbocysteine in syrup based on its reaction with 1-fluoro-2,4-dinitrobenzene monitored with a fluoride-selective electrode
  10. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys)
  11. Identification of the “major” polymorphic carbocysteine metabolite as S-(carboxymethylthio)-l-cysteine
  12. Neltenexine versus carbocysteine in the treatment of exacerbations of mild chronic obstructive pulmonary disease: A randomized, controlled, open-label study
  13. S-Carbocysteine-lysine salt monohydrate and cAMP cause non-additive activation of the cystic fibrosis transmembrane regulator channel in human respiratory epithelium
  14. Spectrophotometric determination of cysteine and/or carbocysteine in a mixture of amino acids, shampoo, and pharmaceutical products using p-benzoquinone
  15. Bioavailability of two formulations of carbocysteine in healthy volunteers
  16. Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness
  17. Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells
  18. Cochrane Database of Systematic Reviews (Reviews) || Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease
  19. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases
  20. Cochrane Database of Systematic Reviews (Reviews) || Acetylcysteine and carbocysteine for acute respiratory tract infections in paediatric patients without chronic bronchopulmonary disease
  21. Carbocysteine regulates innate immune responses and senescence processes in cigarette smoke stimulated bronchial epithelial cells
  22. Synthesis, chemical identification, antioxidant capacities and immunological evaluation studies of a novel silver(I) carbocysteine complex

8 other products in the same category:

arrow_upward